LifeMine operates in Cambridge and Manhattan, New York and was founded in 2016 by Greg Verdine. LifeMine as of 2017 was the first company to massively scale the genomic discovery of new drugs from eukaryotic microbes by using genomics, artificial intelligence and synthetic biology in combination. According to co-founder and CEO Gregory Verdine, the fungal biosphere holds promise for medical treatments in bioactive small molecules that engage human targets but the process of discovery has been time-consuming. LifeMine’s discovery engine is accelerating the discovery process.
Verdine is Erving Professor at Harvard University and Harvard Medical School, a chemical biologist, and founded several biotech companies including FogPharma, Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, Aileron and Gloucester Pharmaceuticals which was acquired by Celgene.
On September 18, 2017 LifeMine Therapeutics completed their series A funding round with $55 million in funding from WuXi Healthcare Ventures (lead investor), Merck & Co., Inc., GV, Foresite Capital, Boyu Capital, Blue Pool Capital, Alexandria Venture Investments, and ARCH Venture Partners.
BRIAN BOWMAN , PhD
VP, Genomic Discovery
Gregory L. Verdine, PhD
Founder, President, CEO and CSO
Hingge Hsu M.B.A., M.D., M.B.A.
HOWARD YOUNG, MBA
PAUL SECRIST, PhD
Weiqing Zhou M.B.A.
LifeMine Therapeutics combines AI, drug discovery & microbes with $55m launch